Syndax Pharmaceuticals Valuation
| 1T3 Stock | EUR 13.40 0.20 1.52% |
At this time, the company appears to be overvalued. Syndax Pharmaceuticals has a current Real Value of €10.99 per share. The regular price of the company is €13.4. Our model measures the value of Syndax Pharmaceuticals from inspecting the company fundamentals such as Operating Margin of (0.11) %, shares outstanding of 68.1 M, and Return On Equity of -0.0519 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Syndax Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Syndax Pharmaceuticals is based on 3 months time horizon. Increasing Syndax Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Syndax stock is determined by what a typical buyer is willing to pay for full or partial control of Syndax Pharmaceuticals. Since Syndax Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Syndax Stock. However, Syndax Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.4 | Real 10.99 | Hype 13.4 | Naive 13.81 |
The real value of Syndax Stock, also known as its intrinsic value, is the underlying worth of Syndax Pharmaceuticals Company, which is reflected in its stock price. It is based on Syndax Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Syndax Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Syndax Pharmaceuticals helps investors to forecast how Syndax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Syndax Pharmaceuticals more accurately as focusing exclusively on Syndax Pharmaceuticals' fundamentals will not take into account other important factors: Syndax Pharmaceuticals Total Value Analysis
Syndax Pharmaceuticals is presently estimated to have takeover price of 979.72 M with market capitalization of 1.67 B, debt of 19.89 M, and cash on hands of 95.37 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Syndax Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
979.72 M | 1.67 B | 19.89 M | 95.37 M |
Syndax Pharmaceuticals Investor Information
About 96.0% of the company shares are owned by institutions such as pension funds. The book value of Syndax Pharmaceuticals was presently reported as 5.62. The company had not issued any dividends in recent years. Based on the key indicators related to Syndax Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Syndax Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in March.Syndax Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Syndax Pharmaceuticals has an asset utilization ratio of 31.07 percent. This implies that the Company is making €0.31 for each dollar of assets. An increasing asset utilization means that Syndax Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Syndax Pharmaceuticals Ownership Allocation
Syndax Pharmaceuticals maintains a total of 68.1 Million outstanding shares. The majority of Syndax Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syndax Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syndax Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syndax Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.Syndax Pharmaceuticals Profitability Analysis
The company reported the revenue of 139.71 M. Net Income was 24.93 M with profit before overhead, payroll, taxes, and interest of 139.71 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Syndax Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Syndax Pharmaceuticals and how it compares across the competition.
About Syndax Pharmaceuticals Valuation
The stock valuation mechanism determines Syndax Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Syndax Pharmaceuticals. We calculate exposure to Syndax Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Syndax Pharmaceuticals's related companies.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax Pharmaceuticals operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 38 people.
8 Steps to conduct Syndax Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Syndax Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Syndax Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Syndax Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Syndax Pharmaceuticals' revenue streams: Identify Syndax Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Syndax Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Syndax Pharmaceuticals' growth potential: Evaluate Syndax Pharmaceuticals' management, business model, and growth potential.
- Determine Syndax Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Syndax Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Syndax Stock analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |